Pictor Holdings Inc. First Anniversary
Analysis based on 6 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026
The strong commercial momentum and successful pre-Series A funding of Pictor Holdings Inc. are likely to positively impact the biotechnology and animal health markets by introducing advanced proteomic solutions. The planned Series A funding of up to $30 million indicates significant future growth and potential for innovation in disease detection, which could attract further investment in the sector.
Pictor Holdings Inc., a global targeted proteomic platform company, is celebrating its first anniversary of opening its U.S. headquarters in Carlsbad, California. In its first year, Pictor has achieved significant commercial and operational milestones, including expanding its product menu to seven commercial off-the-shelf products, securing four strategic partnerships (one with a top 20 global pharmaceutical company and another with Disease Research Limited in New Zealand), and completing a $5M pre-Series A convertible note. The company also expanded its Carlsbad facility with a purpose-built lab and strengthened its U.S. leadership team by welcoming Terence Kelly as COO and Jim Shannon as CFO. Pictor's platform analyzes up to 20 protein targets in a single sample, offering a faster and more cost-efficient alternative to traditional testing. The company is now targeting a U.S. Series A funding round of up to $30 million to further scale its operations, expand its team and patent portfolio, and advance translational studies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard